NASDAQ: ORICOric Pharmaceuticals Inc Stock
$4.77+0.08 (+1.71%)
Updated Apr 17, 2025
ORIC Price
$4.77
Fair Value Price
$0.85
Market Cap
$338.80M
52 Week Low
$3.90
52 Week High
$14.67
P/E
-2.61x
P/B
1.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$127.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$113M
Beta
1.1
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ORIC Overview
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ORIC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ORIC
Ranked#364 of 463
Ranked#364 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important ORIC news, forecast changes, insider trades & much more!
ORIC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ORIC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORIC ($4.77) is overvalued by 459.88% relative to our estimate of its Fair Value price of $0.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORIC ($4.77) is not significantly undervalued (459.88%) relative to our estimate of its Fair Value price of $0.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORIC due diligence checks available for Premium users.
Valuation
ORIC fair value
Fair Value of ORIC stock based on Discounted Cash Flow (DCF)
Price
$4.77
Fair Value
$0.85
Overvalued by
459.88%
ORIC ($4.77) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORIC ($4.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ORIC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.61x
Industry
-177.72x
Market
27.98x
ORIC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.39x
Industry
4.05x
ORIC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ORIC's financial health
Profit margin
Revenue
$0.0
Net Income
-$36.3M
Profit Margin
0%
ORIC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$274.1M
Liabilities
$31.0M
Debt to equity
0.13
ORIC's short-term assets ($262.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORIC's short-term assets ($262.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORIC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORIC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.1M
Investing
$42.7M
Financing
$575.0k
ORIC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORIC vs Biotech Stocks
Oric Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.